Original article
This article aims to shed light on the GKV pharmaceuticals market using selected key figures. In addition to statements about the overall market, individual aspects, such as the regional market shares of various segments, are also examined in more detail. The top companies of 2013 are also presented for various market segments. Together with other data, the analysis carried out by INSIGHT Health provides an insight into current market activity.
08.10.2014
The qualified economist Thomas Ballast is a “health insurance man”: in 1992 he was a consultant for “medical care” at the Federal Association of Guild Health Insurance Funds, in 1995 he was head of the “Doctors” department at the VdAK, and in 2008 he was chairman of the board of the Association of Replacement Insurance Funds. V. (vdek) and since 2012 deputy chairman of the board of the Techniker Krankenkasse. Here he is responsible for the outpatient and inpatient care, information technology and internal services divisions as well as for the health sciences department, the strategic care management department and for the procurement and data protection departments.
04.06.2014
At the last Federal Council meeting before the summer break, following a recommendation from the Health Committee, the majority in the Federal Council voted in favor of implementing a National Diabetes Plan (NDP), supported by an initiative from the federal states of Schleswig-Holstein, Baden-Württemberg, Lower Saxony and Thuringia. “Today is a special, almost historic day for German diabetology because we have initiated an opinion-forming process at the federal level. Nevertheless, we know that we have not yet quite reached the goal of establishing a national diabetes plan. Now it’s the federal government’s turn,” explains Prof. Dr. med. Thomas Danne, CEO of diabetesDE. The history of the NDPs is long, not only in Germany but also in Europe, as they have been called for since 1989 in the St. Vincent Declaration (supported by WHO Europe) and in 2006 by the Council of the European Community and the United Nations. Morten Frank Pedersen, Senior Counsel for Government Affairs and Trade Policy Relations at the research-based pharmaceutical company Novo Nordisk, has been accompanying this often quite difficult process for many years. He knows the problems and developments in the individual European countries very well and explains the background in the MVF interview.
04.06.2014
In Germany, around 10,000 strokes per year could be prevented. This is shown by the stroke care report presented for the first time by DAK-Gesundheit, which highlights the entire care chain for ischemic cerebral infarction - from primary prevention through treatment to rehabilitation. In this report, the first in a series of reports intended to look at current care in a number of focus indications in Germany from a new perspective, the IGES Institute commissioned to do so is based on the methodological model of the so-called “Generalized Cost-Effectiveness Analysis”. which was developed by the World Health Organization (WHO) as part of the “WHO-CHOICE” research program.
04.06.2014
As an information service provider for the Federal Ministry of Health, the German Institute for Medical Documentation and Information (DIMDI) is responsible, among other things, for the publication (and in some cases further development) of official classifications and medical terminologies. It is responsible for parts of the ministry's IT platform, manages cross-agency IT projects and operates various extensive information systems (e.g. on drugs, medical devices, health technology assessments) and supplementary databases; This also applies to the supply data information system (data transparency), which began pilot operation in February 2014. DIMDI director Dr. Dietrich Kaiser and Dr. Jochen Dreß, who is largely responsible for the project on the supply data information system, answered questions from “Monitor Supply Research” about the current approach to making the so-called DaTraV data available.
04.06.2014
In 1999 Dr. Klaus Cichutek, biochemist and adjunct professor of biochemistry at the Johann Wolfgang Goethe University Frankfurt, the role of permanent representative of the president of the Paul Ehrlich Institute (PEI), from October 31, 2001 to November 30, 2009 he was vice president, He has been President of the Paul Ehrlich Institute since December 1, 2009. Prof. Cichutek gave a lecture at the AMNOG conference that received extraordinary applause.
04.06.2014
The motto “Palliative - Care - Research” of the joint 10th Congress of the German Society for Palliative Medicine and the 13th German Congress for Health Care Research was chosen carefully and with an eye to the future. This was made clear by Prof. Dr. Edmund AM Neugebauer, Chairman of the German Network for Health Care Research (DNVF) and Prof. Dr. Friedemann Nauck, President of the German Society for Palliative Medicine, in a joint “introductory game” which – including exchanging jerseys – was entirely in the spirit and language of the Football World Cup, which was still ongoing at the time. Nauck wore jersey number 20 (for 20 years of DGP) and Neugebauer wore jersey number 8 (for 8 years of DNVF).
04.06.2014
The discussion about the transparency of clinical study reports (CSR) continues. The European Medicines Agency (EMA) has an important role to play here, as it is – actually – committed to “complete transparency” when it comes to access to study data. In May of this year, however, the EMA caused great dismay among the professional public with an interim version of its transparency policy. CSR data should therefore only be viewed by third parties on the screen, but not saved, copied or edited. After scientists, and not least the European Ombudsman Emily O'Reillly, criticized the EMA's departure from its original transparency course, the authority revised this restriction. “MVF” asked Prof. Antes, director of the German Cochrane Center, for his opinion on the EMA’s zigzag course.
04.06.2014
Biopharmaceuticals have become an integral part of the drug therapy of many diseases. With increasing sales in this market, biopharmaceuticals are responsible for a significant portion of statutory health insurance drug expenditure. For this reason, the timely market launch of biosimilars after the patent expiry of the original preparations is of crucial importance. Biosimilar manufacturers and various health insurance companies have great interest in steadily and comprehensively increasing the biosimilar market share. The analysis by INSIGHT Health shows that care in Germany is not uniform.
04.06.2014
The 10th Congress of the German Society for Palliative Medicine and the 13th German Congress for Health Services Research took place together in Düsseldorf in June under the motto “Palliative - Care - Research”, also to show that palliative medicine and hospice work are not just based on the idea of evidence , but also want to devote more attention to health services research. 300 abstracts from palliative medicine and hospice work and a further 150 from health services research proved the initiators - the German Society for Palliative Medicine (DPG) and the German Network for Health Care Research (DNVF) - right. “Monitor Healthcare Research” spoke to one of the three congress presidents, Prof. Dr. Raymond Voltz, director of the Center for Palliative Medicine at the University Hospital of Cologne.